diabetes
Conditions
Interventions
diabetes:observational
Sponsors
Shanghai Sixth People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: (1) type 2 diabetes mellitus; (2) mydriasis fundus examination found that the macular area was significantly elevated; the macular foveal thickness (CMT) greater than 250 gm was diagnosed as DME by OCT in the macular fovea; (3) The best corrected visual acuity In 20/30 recommended anti-VEGF drug treatmen; (4) did not have any fundus treatment; (5) no retinal vein occlusion, glaucoma and other medical history; (6) Good general condition.;Inclusion criteria: (1) type 2 diabetes mellitus; (2) mydriasis fundus examination found that the macular area was significantly elevated; the macular foveal thickness (CMT) greater than 250 gm was diagnosed as DME by OCT in the macular fovea; (3) The best corrected visual acuity In 20/30 recommended anti-VEGF drug treatmen; (4) did not have any fundus treatment; (5) no retinal vein occlusion, glaucoma and other medical history; (6) Good general condition.
Exclusion criteria
Exclusion criteria: (1) macular edema caused by other causes than diabetes; (2) cloudy ophthalmology due to cataract or other reasons; (3) retinal laser photocoagulation after receiving vitreoretinal surgery or retinal detachment within 3 months; (4) the target eye with proliferative diabetic retinopathy (PDR); (5) the target eye with vitreous hemorrhage within 2 months before screening; (6) the target eye with iris neovascularization; (7) Uncontrolled Hypertension or HbA1c> 12% poor glycemic control; (8) Cerebrovascular accident or MI within the last 3 months; (9) A history of anaphylaxis or allergy to sodium fluorescein, A history of allergy to protein preparations for treatment or diagnosis, allergy to two or more drugs and / or non-drug agents, or allergic diseases.;Exclusion criteria: (1) macular edema caused by other causes than diabetes; (2) cloudy ophthalmology due to cataract or other reasons; (3) retinal laser photocoagulation after receiving vitreoretinal surgery or retinal detachment within 3 months; (4) the target eye with proliferative diabetic retinopathy (PDR); (5) the target eye with vitreous hemorrhage within 2 months before screening; (6) the target eye with iris neovascularization; (7) Uncontrolled Hypertension or HbA1c> 12% poor glycemic control; (8) Cerebrovascular accident or MI within the last 3 months; (9) A history of anaphylaxis or allergy to sodium fluorescein, A history of allergy to protein preparations for treatment or diagnosis, allergy to two or more drugs and / or non-drug agents, or allergic diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| changes of intra-retinal layers;;changes of intra-retinal layers; | — |
Countries
China
Contacts
Public ContactXiangning Wang;Xiangning Wang ;
Shanghai Sixth People's Hospital ;Shanghai Sixth People's Hospital
Outcome results
None listed